Long-term Outcomes of Augmentation Enterocystoplasty in Patients With End-Stage Bladder Diseases: A Single-Institute Experience Involving 102 Patients.
- Author:
Shu Yu WU
1
;
Yuan Hong JIANG
;
Hann Chorng KUO
Author Information
- Publication Type:Original Article
- Keywords: Lower Urinary Tract Symptoms; Urinary Bladder Diseases; Cystitis; Urinary Bladder, Neurogenic
- MeSH: Compliance; Cystitis; Follow-Up Studies; Hospitals, General; Humans; Intermittent Urethral Catheterization; Lower Urinary Tract Symptoms; Meningomyelocele; Patient Satisfaction; Pelvic Neoplasms; Quality of Life; Retrospective Studies; Spinal Cord Injuries; Urinary Bladder Diseases*; Urinary Bladder*; Urinary Bladder, Neurogenic; Urinary Incontinence; Urinary Tract; Urinary Tract Infections
- From:International Neurourology Journal 2017;21(2):133-138
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Augmentation enterocystoplasty (AE) has been shown to improve clinical symptoms in patients with end-stage bladder disease (ESBD). Herein, we report the long-term outcomes of a series of patients with different etiologies of ESBD who received AE. METHODS: We retrospectively reviewed 102 patients with ESBD who received AE at the Hualien Tzu Chi General Hospital from 1992 to 2014. ESBD in this study was defined as including neurogenic lower urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI) or myelomeningocele, inflammatory bladder disease (IBD), ESBD occurring after pelvic cancer surgery, and other etiologies. Complications including active lower urinary tract problems and urinary tract infection (UTI), as well as patients’ self-reported satisfaction with the procedure, were evaluated. RESULTS: A total of 102 patients were included in the study. A majority of patients received AE for NLUTD (n=43), followed by IBD (n=38), ESBD after pelvic cancer surgery (n=15), and the other etiologies (n=6). Patients had a mean age of 39.4±18.7 years and were followed for a mean of 78 months. All patients had significantly increased cystometric bladder capacity and compliance at the time of follow-up. Fifty-four patients (52.9%) reported moderate to excellent satisfaction with the outcome, and there were no significant differences among the groups (P=0.430). The most common reason for dissatisfaction was the need for clean intermittent catheterization (CIC; 41.7%), followed by urinary incontinence (25.0%) and recurrent UTI (16.7%). CONCLUSIONS: AE is a safe and effective procedure for patients with ESBD. Postoperative urinary incontinence and UTI as well as the need for CIC may affect quality of life and decrease patient satisfaction.
